Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

624.O1.8 New and Emerging Biologic Therapies of NHL

Monday, December 8, 2008: 7:00 AM-9:00 AM
3001-3003-3005 - West (Moscone Center)
Moderators:
Armando López-Guillermo, 423180 and John F Seymour, MB, BS, PhD, FRACP
7:00 AM
Post-Transplant Lymphoproliferative Disorder: Evaluation of Effectiveness of Reduction of Immunosuppression or Systemic Chemotherapy

Parneet K Cheema, MD1*, Sahar Zadeh2*, Heather Ross, MD3*, Edward Cole, MD3*, Shaf Keshavjee, MD3*, Gary Levy, MD3* and Michael Crump, MD2

1Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada
2Princess Margaret Hospital, Toronto, ON, Canada
3University Health Network, University of Toronto, Toronto, ON, Canada

7:15 AM
Complete Tumor Responses in Lymphoma Patients Who Receive Autologous Cytotoxic T Lymphocytes Targeting EBV Latent Membrane Proteins

Catherine M. Bollard, MD1, Maja Stanojevic, BS1*, Ann M. Leen, PhD1, Teresita Lopez, BS1*, Andrea N. Sheehan, MD2*, George Carrum, MD1*, Hao Liu, PhD1*, Chung-Che Chang, MD3*, Adrian P. Gee, PhD1, Malcolm K. Brenner, MD, PhD1*, Cliona M. Rooney, PhD1*, Helen E. Heslop, MD1* and Stephen Gottschalk, MD1*

1Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, and Texas Children's Hospital, Houston, TX
2Department of Pathology, Baylor College of Medicine, Houston, TX
3Department of Pathology,, Weill Medical College of Cornell University, Houston, TX

7:30 AM
Yttrium-90 Radiolabeled Humanized Monoclonal Antibody to CD25 in Refractory and Relapsed Hodgkin's LymphomaClinically Relevant Abstract

Deirdre O'Mahony, MD1, John E Janik, MD1*, Jorge A. Carrasquillo, MD2*, Pamela Seam, MD1*, Joseph A Fiorillo, MD1*, Donn Stewart, MD1*, Chang H Paik, PhD2*, Suzanne Fioravanti, RN1*, Millie Whatley, RNMT2*, Stefania Pittaluga, MD, PhD3, Martin W Brechbiel, PhD4*, John C Morris, MD1* and Thomas A Waldmann, MD1*

1Metabolism Branch,, National Cancer Institute, Bethesda, MD
2Department of Nuclear Medicine, Center for Cancer Research, National Cancer Institute, Bethesda, MD
3Laboratory of Pathology, NCI, NIH, Bethesda, MD
4Radiation Oncology Branch, Centre for Cancer Research, National Cancer Institute, Bethesda, MD

7:45 AM
Serious Pulmonary Toxicity with SGN-30 and Gemcitabine, Vinorelbine, and Liposomal Doxorubicin in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL): Cancer and Leukemia Group B (CALGB) 50502

Kristie A. Blum, MD1, Jeffrey L Johnson2*, Sin-Ho Jung2*, Bruce D. Cheson, MD3 and Nancy L. Bartlett, MD4

1Division of Hematology/Oncology, Ohio State University, Columbus, OH
2CALGB Statistical Office, Duke University Medical Center, Durham, NC
3Lombardi Cancer Ctr., Georgetown Univ. Hosp., Washington, DC
4Washington University, Saint Louis, MO

8:00 AM
Phase I Dose-Escalation Trial of BI 2536, a Polo-Like Kinase 1 Inhibitor, in Relapsed and Refractory Non-Hodgkin’s Lymphoma

Julie M. Vose1, Anas Young2*, Jonathan W. Friedberg3, Edmund K. Waller4, Bruce D. Cheson5, Dirk Trommeshauser6* and Gerd Munzert6*

1University of Nebraska Medical Center, Omaha, NE
2M.D. Anderson Cancer Center, Houston, Houston, TX
3University of Rochester, Rochester, NY
4Emory University, Winship Cancer Institute, Atlanta, GA
5Georgetown University Hospital, Washington, DC
6Boehringer Ingelheim Pharma GmbH & Co., KG, Biberach, Germany

8:15 AM
A Phase I/II Study of RO5072759 (GA101) in Patients with Relapsed/Refractory CD20+ Malignant Disease

Gilles Andre Salles, MD, PhD1, Franck Morschhauser, M.D.2*, Guillaume Cartron, M.D.3*, Thierry Lamy, MD, PhD4, Noel-Jean Milpied, M.D., PhD5, Catherine Thieblemont, M.D.6, Hervé Tilly, M.D.7*, Joe Birkett, Ph.D.8* and Mike Burgess, M.D.8*

1Hematologie, Centre Hospitalier Lyon-Sud, Pierre-Benite, France
2Hematology, Centre Hospitalier Universitaire, Lille, France
3Haematology-Oncology, INSERM U847 and CIC BT 509, University Hospital, Montpellier Cedex 5, France
4Service Hematologie Clinique, Hospital Pontchaillou, Rennes, France
5Hopital Haut Leveque - Pessac, Pessac, France
6Hemato-Oncology, Hopital Saint-Louis, APHP - INSERM U 728 - Institut Universitaire d'Hematologie, Paris, France
7Hematologie, CENTRE HENRI BECQUEREL, Rouen, France
8CRED Oncology, F.Hoffmann-La Roche, Ltd., Welwyn Garden City, United Kingdom

8:30 AM
Idiotype Vaccination of Untreated Indolent B-Cell Lymphoma: Durable Objective Remissions and Association of Superior Outcome with Cellular Immune Responses

Marcelo A. Navarrete, MD*, Kristina Heining-Mikesch, MD*, Cristina Bertinetti-Lapatki, PhD*, Marcus Duehren-von Minden*, Andrea Hafkemeyer, MD* and Hendrik Veelken, MD

Department of Hematology/Oncology, University Medical Center Freiburg, Freiburg, Germany

8:45 AM
A Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy with Mitumprotimut-T (ID-KLH) and GM-CSF Following Rituximab in Patients with CD20+ Follicular LymphomaClinically Relevant Abstract

Arnold S. Freedman, MD1, Sattva Neelapu, MD2, Craig R Nichols, MD3*, Michael Robertson, MD4, Benjamin Djulbegovic, MD, PhD5, Jane N. Winter, MD6, Daniel Gold, PhD7*, John Bender, PharmD8, Morgan Stewart, PhD9*, Richard G. Ghalie, MD, MBA9* and Paul A. Hamlin Jr., MD10

1Dana-Farber Cancer Inst., Boston, MA
2Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center, Houston, TX
3Providence Cancer Center, Portland, OR
4Indiana Univ. Medical Center, Indianapolis, IN
5H. Lee Moffitt Cancer Center, Tampa, FL
6Feinberg School of Medicine, Northwestern University, Chicago, IL
7Favrille, Inc., San Diego, CA
8Favrille Inc., San Diego, CA
9Favrille, Inc, San Diego, CA
10Memorial Sloan-Kettering Cancer Ctr., New York, NY

*signifies non-member of ASH